Kras is the most frequently mutated ras family member in lung carcinomas 1, 2 , whereas Hras mutations are common in tumors from stratified epithelia such as the skin. Using a Hras knock-in mouse model 3 , we demonstrate that specificity for Kras mutations in lung and Hras mutations in skin tumors is determined by local regulatory elements in the target ras genes. Although the Kras 4A isoform is dispensable for mouse development 4, 5 , it is the most important isoform for lung carcinogenesis in vivo and for the inhibitory effect of wild-type (WT) Kras on the mutant allele 6, 7 . Kras 4A expression is detected in a subpopulation of normal lung epithelial cells, but at very low levels in lung tumors, suggesting that it may not be required for tumor progression. The two Kras isoforms undergo different post-translational modifications 8 ; therefore, these findings can have implications for the design of therapeutic strategies for inhibiting oncogenic Kras activity in human cancers.
Kras deficiency in mice leads to embryonic lethality 4, 5 ; thus, it has not been possible to determine whether the selection for Kras mutations in lung tumors reflects a specific oncogenic function that is required for lung carcinogenesis and that cannot be compensated for by mutant Hras or Nras. The Hras knock-in mouse provides a viable model that completely lacks Kras expression 3 (Fig. 1) but carries a 'knock-in' Hras cDNA expressed under the control of Kras regulatory elements. We reasoned that Hras knock-in mice should be resistant to lung tumor development if Kras protein is essential for lung carcinogenesis. To control for the possibility of structural alterations affecting experimental outcomes, we used Kras knock-in mice in which the coding sequence corresponding to the Kras 4B isoform was knocked back into the Kras locus in the exact manner used to generate the Hras knock-in mouse 3 . Hras knock-in mice expressed elevated levels of Hras protein, consistent with the increase in Hras gene dosage from two copies to four in these animals ( Fig. 1) . Kras knock-in mice expressed similar levels of Kras protein as WT mice, as expected because Kras 4B is the major splice isoform 9, 10 . Levels of Akt and Erk activation in these animals were similar to those in WT mice (Fig. 1) . There was also no difference in levels of p38a, recently shown to affect ras-mediated lung carcinogenesis 11 . The elevated level of Hras therefore does not affect the major downstream effector pathways relevant to cancer development.
We treated Hras KI homozygous and heterozygous mice and WT littermates with urethane and killed the animals 20 weeks later for analysis. Unexpectedly, we found that Hras KI homozygous mice developed Btenfold more lung tumors than WT littermate controls (44.8 ± 11.7 vs. 4.7 ± 2.9; Fig. 2 14 . However, we never found the endogenous Hras gene to be mutated in urethane-induced lung tumors. The occurrence of Hras mutations in lung tumors therefore is completely dependent on Hras being expressed from the Kras locus.
We further pursued the specificity of ras gene mutations in lung and skin tumors by inducing both tumor types in the same Hras KI homozygous mice. A single dose of urethane was injected intraperitoneally to induce lung tumors, followed by a single topical treatment on the skin with urethane and subsequent biweekly application of tetradecanoyl-phorbol acetate (TPA) to induce papilloma development. All lung tumors (n ¼ 28) analyzed had the CAA4CTA mutation in the Hras KI allele. Of the papillomas (n ¼ 20) developed in these same mice, 15 (75%) carried the CAA4CTA mutation in the endogenous Hras gene on chromosome 7, consistent with previous studies 14, 15 . Of the remaining five papillomas, four (20%) contained the CAA4CTA mutation in the Hras KI allele. Mutations in the endogenous Kras gene are rarely seen in WT mice, but the frequency is increased in Hras -/-mice where no endogenous Hras target is available 16 . Regulatory elements in Kras are therefore capable of directing expression to at least a subset of target cells within the epidermis, but the overall preference is strongly in favor of Hras. These results indicate that the mechanisms underlying Kras mutation selection in lung cancer and Hras in skin cancer involve cis-acting regulatory elements specific to each gene rather than functional differences between the encoded proteins. Previous studies have demonstrated the existence of multiple sequence variants in the mouse Kras gene that may potentially affect regulation of expression 17 , and further studies would be required to identify the specific element(s) involved.
As with other Kras models of lung tumor development 12, 13 , Hras knock-in mice developed papillary adenomas (Fig. 3a) , but also significantly more mixed adenomas (Fig. 3b ) and solid adenomas (Fig. 3c) , sometimes with intrabronchiolar extension (Fig. 3c, inset) . Many of the solid adenomas contain cells with epithelioid morphology (Fig. 3d,e )-large, plump cells with eccentrically located nuclei and abundant cytoplasm ranging from finely granular and eosinophilic to microvesicular and amphophilic. Positive cytokeratin 8/18 staining ( Fig. 3f) and negative periodic acid-Schiff (PAS) staining (Fig. 3g) showed that the vast majority of these cells were epithelioid, nonmucinous tumor cells. These solid epithelioid tumors stained positive for SP-C (Fig. 3h) and negative for CCA/CC10 (Fig. 3i) , like tumors from urethane-treated WT mice and other mouse models of lung cancer 12, 13, 18 . Both Kras 4A and Kras 4B splice variants are present in normal lungs, but Kras 4B is clearly the more abundant isoform 9, 10 . However, Kras KI homozygous mice that express only Kras 4B proved to be highly resistant to urethane-induced lung tumor formation (Fig. 4a) . Of ten Kras KI homozygous mice examined, eight did not develop any surface lung tumors. Two mice developed one and two small tumors each, but none of the tumors contained a mutation in the Kras KI allele or in the endogenous Hras or Nras genes. Consistent with our findings, mice with a genomic knockout of exon 4A, and therefore able to express only Kras 4B, showed a marked decrease in lung tumor number following treatment with N-methyl-N-nitrosourea 19 .
Tumors from mice heterozygous for the Kras KI allele were also positive for SP-C and negative for CCA/CC10 ( Supplementary Fig. 1  online) . Kras mutations were present in 24 of 33 tumors (73%) from Kras KI heterozygous mice, but in all 24 cases the mutation occurred in the endogenous Kras gene (which retains both Kras 4A and Kras 4B) and not in the Kras KI allele (which expresses exclusively Kras 4B) (P ¼ 6.2 Â 10 À14 , Fisher's exact test). These findings are consistent with the resistant phenotype of Kras KI homozygous mice and indicate that oncogenic mutations involving only Kras 4B do not provide the necessary advantage required for tumorigenesis. As both Kras 4A and Kras 4B transcripts are present in lungs of mice containing the intact Kras gene 9,10 , our results suggest that the transforming effect of Kras mutations during lung carcinogenesis in vivo are mediated primarily through the activity of the Kras 4A protein.
Kras 4A and Kras 4B isoforms differ only at their C termini, resulting in differences in post-translational modifications 8 . Kras 4A and Hras proteins undergo similar post-translational modifications and therefore are localized within similar microdomains in the membrane, distinct from those involving Kras 4B 8, 20 . The similarities of Kras 4A and Hras in this respect correlate with their ability to induce lung tumors in WT and Hras knock-in mice, respectively. In vitro studies have also demonstrated that mutant Kras 4A and Hras are more potent oncogenes than mutant Kras 4B 21, 22 .
The WT ras alleles in tumors that contain ras mutations are frequently deleted, and/or the mutant allele is amplified [23] [24] [25] . The possibility of a tumor suppressor function for WT Ras proteins has been supported by in vitro functional assays 26 and in vivo genetic studies involving genetically engineered mice 6, 7 . These studies demonstrated that WT Kras can potently suppress the activity of oncogenic Kras to regulate lung tumor development 6, 7 . We found that Kras KI heterozygous mice developed Btwofold more lung tumors than WT mice (Fig. 4a) . This observation, together with results from our mutational analysis, suggested that the Kras KI allele may be less efficient in this suppressor activity. To further test this idea, we bred Kras KI heterozygous mice with Kras LA2 mice 13 , which undergo spontaneous recombination to activate Kras and do not require carcinogen treatment. The genotypes tested included animals with one Kras LA2 allele and either a WT Kras gene or a Kras KI allele. Kras LA2 mice carrying a Kras KI allele developed significantly more lung tumors than those that are able to express Kras 4A isoform from the WT Kras gene (Fig. 4b) . Notably, the Hras KI allele is also more effective than the Kras KI allele in suppressing tumor multiplicity in Kras LA2 mice, indicating that it can substitute for Kras 4A in suppressor activity in vivo. Although in vitro work has shown that overexpressed WT Kras 4B has inhibitory effects 6 , our collective in vivo findings suggest that efficient suppression of oncogenic Kras activity requires an intact WT Kras locus that is capable of generating the Kras 4A isoform. Studies of human tumors have shown that Kras 4B is the more abundant splice variant and, in fact, that levels of Kras 4A may be even further reduced compared to Kras 4B in tumors carrying Kras mutations 27 . This is in apparent contradiction to our genetic evidence for a major role of the Kras 4A isoform in lung carcinogenesis. We therefore investigated the localization of Kras 4A expression in normal lung and lung tumors. Using an antibody specific for Kras 4A, we detected expression in a subpopulation of Clara cells throughout the bronchial tree, including at the bronchio-alveolar junctions (Fig. 5a,b) . Similar sections from mice homozygous for the Kras KI allele (Fig. 5c) or the Hras KI allele (not shown), both of which lack Kras 4A, were negative. Antibodies against Kras 4B yielded nonspecific signals, as positive staining was observed even in sections from Hras KI homozygous mice that completely lack Kras expression (data not shown). The bronchio-alveolar junctions have been reported to contain the putative bronchio-alveolar stem cells (BASCs) 28 , but Kras 4A-positive cells are certainly more abundant than BASCs. Sections of tumors from WT mice, however, showed almost no detectable signal for Kras 4A protein (Fig. 5d) , although low expression was detected at the RNA level, as previously described for human cancers 27 . It is possible that Kras 4A expression may affect the stem cell fate decision leading to the adenocarcinoma lineage, but further detailed studies will be required to elucidate the relationship between Kras isoform expression and lung stem cells. Of note, differential roles for Kras 4A and Kras 4B have previously been proposed in embryonic stem cell differentiation 9 , but there are presently no data on adult stem cells.
Inhibitors targeting specific Ras post-translational events, in particular farnesylation, have not been successful in clinical trials, the reasons for which are unclear. Nevertheless, in vitro studies, as well as mouse models, strongly suggest that the activity of oncogenic Ras proteins can be effectively inhibited through manipulation of their carboxyl domains 8, 20 . The identification of Kras 4A, and not Kras 4B as previously thought, as the main mediator of both the oncogenic activity of mutant Kras and the suppressor activity of WT Kras provides new opportunities for designing and testing novel targeted therapies.
METHODS
Mouse breeding and carcinogenesis. The Hras KI and Kras KI alleles were generated, and subsequently maintained, in a 129/Sv background. Animals heterozygous for the Hras KI or Kras KI allele were intercrossed to generate WT and Hras KI and Kras KI heterozygous or homozygous animals. Genotyping of mice was done on DNA extracted from tail clippings (see Supplementary  Table 2 online for PCR primer sequences). Chemical carcinogenesis of the lungs and skin was done as previously described 2, 7, 14, 15 . Kras LA2 mice (on FVB/ N background) were bred with Kras KI heterozygous mice, and all mice that inherited Kras LA2 were selected for analysis. Animals were killed at 4 months of age for analysis.
All mouse experiments were approved by the University of California San Francisco Laboratory Animal Resource Center.
Mutational analysis. Lung tumors were dissected from fixed lungs under a dissecting microscope, and genomic DNA was purified by phenol/chloroform extraction following proteinase K digestion. We detected mutations by sequencing of PCR products corresponding to the endogenous Kras, Hras KI and Kras KI fragments containing the mutation hot spots at codon 12, 13 or 61 (Supplementary Table 2 for primer sequences). As the mutation in Hras KI and Hras was found by sequencing to be exclusively the CAA4CTA alteration at codon 61, we took advantage of the XbaI digestion assay to detect this mutation 29 .
Immunoblotting. Protein lysates of lung tissues were prepared as previously described 30 . Immunoblots were probed with antibodies against Kras (F234 and C-19), Hras (C-20), Nras (C-20) and Erk1 (C-16) from Santa Cruz Biotechnology; phospho-p44/p42 Map Kinase, Akt, and ap38 from Cell Signaling; b-actin from Sigma; and phospho-Akt from D. Stokoe (University of California San Francisco).
Immunohistochemistry. Sections were deparaffinized and antigen retrieval was done in 10 mM sodium citrate solution (pH 6). Endogenous peroxidase was quenched with a 3% H 2 O 2 solution (Sigma) for 10 min at room temperature, and blocking was performed with 5% goat serum (Zymed) diluted in PBS containing 0.1% Tween-20 for 1 h at room temperature. We carried out overnight incubation with the primary antibodies against CCA/CC10 (a gift from A. Mukherjee, National Institute of Child Health and Human Development, US National Institutes of Health), SP-C (Chemicon) and Kras 4A (Santa Cruz Biotechnology) at 4 1C. After washing in PBS containing 0.1% Tween-20 (PBS-T), sections were incubated with a biotinylated secondary antibody to rabbit (Vector) at a dilution of 1:200 for 1 h at room temperature. Sections were washed with PBS-T, incubated in Vectastain ABC reagent (Vector) according to the manufacturer's instructions, and developed using DAB.
Note: Supplementary information is available on the Nature Genetics website. 
